The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs).
 
Yoshihiro Mise
No Relationships to Disclose
 
Kiyoshi Hasegawa
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Covidien; Daiichi Sankyo; Hitachi Chemical; Japan Blood Products Organization; Japanese Society of Gastroenterological Surgery; Jichi Medical University Hospital; Kaken Pharmaceutical; Miyarisan Pharmaceutical; MSD K.K; National Clinical Database; Nihon Pharma; Novartis; Otsuka; Sumitomo Dainippon; Taiho Pharmaceutical; Taisho Toyama Pharma; Takeda; Tsumura & Co.
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); MSD K.K (Inst); Nihon Pharma (Inst); Otsuka (Inst); Otsuka (Inst); Shimadzu (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)
 
Masaru Oba
No Relationships to Disclose
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hiroyuki Uetake
Consulting or Advisory Role - Lilly; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Chugai Pharma; Lilly; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); GlaxoSmithKline (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)
 
Satoshi Morita
Honoraria - Bristol-Myers Squibb; Merck; Yakult Pharmaceutical
 
Keiichi Takahashi
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical
 
Michiaki Unno
Honoraria - Chugai Pharma; Novartis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Yasuhiro Shimada
Honoraria - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; TAKEDA; Tsumura & Co.; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD K.K (Inst); Taiho Pharmaceutical (Inst)
 
Kei Muro
Honoraria - Bayer; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Gilead Sciences (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst)
 
Kazuhiro Yoshida
Honoraria - Asahi Kasei; Bayer Yakuhin; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; Intuitive Surgical; Johnson & Johnson; Lilly; Merck Serono; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Johnson & Johnson (Inst); KCI (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst); Toyama Chemical Co (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
 
Masaki Mori
No Relationships to Disclose
 
Hideo Baba
Honoraria - Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Mitsuo Shimada
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Covidien (Inst); CSL Behring (Inst); Japan Blood Products Organization (Inst); Johnson & Johnson (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TSUMURA & CO. (Inst)
 
Akio Saiura
No Relationships to Disclose
 
Masaru Matsumura
No Relationships to Disclose
 
Kiyoshi Ishigure
No Relationships to Disclose
 
Kenichi Sugihara
Honoraria - Chugai Pharma; Lilly; Novartis; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma; Taiho Pharmaceutical
 
Norihiro Kokudo
No Relationships to Disclose